Administration of G‐CSF to WHIM patients, by lowering CXCL12 levels in the bone marrow, is sufficient to cause an increase of circulating neutrophils lasting for hours after the treatment.17 Pharmacologic antagonism of CXCR4 represents a novel approach for the treatment of WHIM patients.18 Indeed, a single dose of AMD3100 can rapidly and transiently increase neutrophil numbers for 1‐9 hours and lasting up to 24 hours in some patients.19 This therapeutic use of AMD3100 in WHIM patients was shown to considerably reduce infection frequency and wart burden.20 Here, CXCR4 is linked to infection.